Avidity Biosciences (RNA) - Cash on Hand

Cash on Hand as of September 2024 : ₹135.47 Billion

According to Avidity Biosciences's latest financial reports the company has ₹135.47 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Avidity Biosciences - Cash on Hand chart (from 2019 to 2024)

Cash on Hand by year

Year	Cash on Hand	Change
2023-12-31	₹49.56 B	-1.93%
2022-12-31	₹50.53 B	67.43%
2021-12-31	₹30.18 B	25.78%
2020-12-31	₹23.99 B	255.82%
2019-12-31	₹6.74 B	3021.56%
2018-12-31	₹0.21 B

Cash on Hand for similar companies or competitors

Company	Cash on Hand	differencediff.	Country
PTC Therapeutics PTCT	₹86.41 B	-36.21%	🇺🇸 USA
Acorda Therapeutics ACOR	₹0.79 B	-99.41%	🇺🇸 USA
Sarepta Therapeutics SRPT	₹102.19 B	-24.56%	🇺🇸 USA
Catalyst Pharmaceuticals CPRX	₹37.72 B	-72.16%	🇺🇸 USA
Fate Therapeutics FATE	₹25.32 B	-81.31%	🇺🇸 USA
Acceleron Pharma XLRN	N/A	N/A	🇺🇸 USA
Pfizer PFE	₹848.70 B	526.47%	🇺🇸 USA
GlaxoSmithKline GSK	₹366.59 B	170.60%	🇬🇧 UK

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions